-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Share
Listen to the news

Gainers

  • Propanc Biopharma (NASDAQ:PPCB) stock rose 52.6% to $2.06 during Thursday's pre-market session. The market value of their outstanding shares is at $3.0 million.
  • 60 Degrees (NASDAQ:SXTP) stock rose 16.66% to $1.61. The company's market cap stands at $3.6 million.
  • Quantum Cyber (NASDAQ:QUCY) shares rose 16.14% to $2.23. The market value of their outstanding shares is at $43.7 million.
  • Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 13.39% to $3.47. The company's market cap stands at $1.2 million.
  • Genenta Science (NASDAQ:GNTA) stock increased by 11.53% to $1.84. The market value of their outstanding shares is at $38.6 million.
  • CEL-SCI (AMEX:CVM) shares rose 9.91% to $1.3. The company's market cap stands at $17.1 million.

Losers

  • Atossa Therapeutics (NASDAQ:ATOS) stock fell 26.1% to $3.25 during Thursday's pre-market session. The company's market cap stands at $37.8 million.
  • Purple Biotech (NASDAQ:PPBT) stock decreased by 23.46% to $2.27. The market value of their outstanding shares is at $2.7 million.
  • Humacyte (NASDAQ:HUMA) shares decreased by 20.9% to $1.06. The company's market cap stands at $297.5 million.
  • GlucoTrack (NASDAQ:GCTK) shares decreased by 20.3% to $0.32. The company's market cap stands at $2.5 million.
  • Aditxt (NASDAQ:ADTX) shares decreased by 17.84% to $0.02.
  • Basel Medical Group (NASDAQ:BMGL) shares fell 14.04% to $0.5. The company's market cap stands at $11.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending